Skip to content

RAPT Therapeutics, Inc.

CIK 0001673772

← back to feed
Revenue (TTM)
$886K
−100.0% YoY Q3 Nov 2025
Net Income (TTM)
−$70.82M
−11.2% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$5.17
−4.6% YoY Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
-8,799.0%
Q3 Nov 2025
Net Margin
-7,993.2%
Q3 Nov 2025
Free Cash Flow (TTM)
−$114.73M
Q3 Nov 2025
Cash
$37.93M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
27.71M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings